A court hearing to consider the transaction’s approval is scheduled for June 17, according to 23andMe Abigail Adams is a Human Interest Writer-Reporter for PEOPLE. Justin Sullivan/Getty; Michael Nagle ...

23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the SEC. The company filed for for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals announced on Monday that it will acquire "substantially all" of genetic testing company 23andMe's assets. The pharmaceutical company said it won the court-supervised auction ...

The sale of 23andMe was finalized this week, following the company filing for bankruptcy in March. The sale was previously approved by a judge. The company was purchased by the nonprofit TTAM Research ...

Genetic testing company 23andMe never hit on a sustainable business model and went bankrupt. Now, it's being sold to a non-profit launched by the co-founder, delaying addressing data privacy concerns.

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

The deadline to submit a claim form for a 23andMe settlement is fast approaching. Millions of customers are expected to receive payouts from a $50 million settlement over a 23andMe customer data ...

Regeneron Pharmaceuticals acquiring genetic testing firm 23andMe for $256 million. The deal follows 23andMe’s Chapter 11 bankruptcy protection filing in March. Transaction excludes telehealth provider ...

Who would want to buy a troubled consumer genetic-testing business with declining revenue and hundreds of millions of dollars in annual losses that exposed millions of users’ genetic information in a ...

Regeneron has agreed to buy 23andMe, the once buzzy genetic testing company, out of bankruptcy for $256 million under a court-supervised sale process. 23andMe declared bankruptcy in March and ...

Genetics testing company 23andMe on Monday announced a deal to be acquired by biotechnology company Regeneron. The $256 million sale is subject to court oversight, and still needs approval. The sale ...